Meta Description: Uterine/endometrial cancer is the most common gynecologic cancer in the U.S. Learn about its hormonal causes, risk factors, warning signs, treatment options, and evidence-based integrative strategies for women's hormonal health.
Introduction
Uterine cancer — most commonly endometrial cancer, arising from the lining of the uterus — is the most common gynecologic cancer in the United States and the fourth most common cancer in women overall. Its incidence has been rising steadily, driven largely by the obesity epidemic and an aging population.
Unlike ovarian cancer, endometrial cancer has a clear early warning sign — abnormal uterine bleeding — which means most cases are caught at an early, highly treatable stage. Understanding the hormonal drivers, risk factors, and integrative strategies for hormonal balance is essential for every woman, particularly those approaching or in menopause.
What Is Uterine/Endometrial Cancer?
The uterus is a pear-shaped organ in the pelvis where a fetus develops during pregnancy. It has two main layers: the endometrium (inner lining) and the myometrium (muscular outer wall).
The vast majority of uterine cancers — approximately 90% — are endometrial carcinomas, arising from the endometrium. These are classified into two main types:
- Type I (Endometrioid adenocarcinoma) — ~80%; estrogen-driven; typically low-grade; excellent prognosis; associated with obesity, diabetes, and unopposed estrogen exposure
- Type II (Non-endometrioid) — ~20%; includes serous carcinoma, clear cell carcinoma, and carcinosarcoma; not estrogen-driven; more aggressive; worse prognosis; more common in older, thinner women and African American women
Less common uterine cancers include uterine sarcomas (arising from the myometrium or connective tissue), which account for ~3–7% of uterine cancers and carry a worse prognosis.
How Common Is It?
- Approximately 67,000 new cases diagnosed annually in the U.S.
- Lifetime risk: roughly 1 in 37 women
- 5-year survival: ~81% overall; ~95% for localized disease
- Incidence has increased by ~1% per year over the past decade
- Mortality is rising, particularly in African American women who have disproportionately higher rates of aggressive Type II tumors
The Estrogen Connection
Type I endometrial cancer is fundamentally a disease of unopposed estrogen — estrogen stimulation of the endometrium without the balancing effect of progesterone. This leads to endometrial hyperplasia (overgrowth) and, over time, malignant transformation.
Sources of unopposed estrogen include:
- Obesity — adipose tissue converts androgens to estrone (a form of estrogen) via aromatase; the most important modifiable risk factor
- Anovulation — irregular or absent ovulation (as in PCOS) means no progesterone production
- Estrogen-only HRT — without progesterone; dramatically increases endometrial cancer risk
- Tamoxifen — acts as an estrogen agonist in the uterus (while blocking it in the breast); increases endometrial cancer risk with long-term use
- Early menarche / late menopause — longer lifetime estrogen exposure
- Nulliparity — pregnancy provides prolonged progesterone exposure
Risk Factors
Non-Modifiable
- Age — most cases diagnosed after 55; median age at diagnosis is 63
- Lynch syndrome (HNPCC) — lifetime risk of endometrial cancer up to 40–60%; most common Lynch-associated cancer in women
- Cowden syndrome — PTEN mutations; significantly increased risk
- Family history of endometrial, colorectal, or ovarian cancer
- Race — White women have higher incidence; African American women have higher mortality due to more aggressive tumor types
Modifiable
- Obesity — the dominant modifiable risk factor; obese women have 2–4x the risk; morbidly obese women have up to 7x the risk
- Type 2 diabetes and insulin resistance — insulin and IGF-1 directly stimulate endometrial cell proliferation
- Polycystic ovary syndrome (PCOS) — chronic anovulation leads to unopposed estrogen
- Estrogen-only HRT — always use combined estrogen + progesterone HRT if the uterus is intact
- Tamoxifen use — women on tamoxifen should have annual gynecologic evaluation
- Sedentary lifestyle
Protective factors: Combined oral contraceptives (reduce risk ~50% with 5+ years of use), pregnancy and breastfeeding, physical activity, healthy weight, IUD use (levonorgestrel-releasing IUDs are protective).
Warning Signs and Symptoms
Endometrial cancer has a critical advantage over most gynecologic cancers: it announces itself early.
- Abnormal uterine bleeding — the hallmark symptom; postmenopausal bleeding (any bleeding after 12 months of amenorrhea) must be evaluated promptly; in premenopausal women, irregular or heavy bleeding warrants investigation
- Watery or blood-tinged vaginal discharge
- Pelvic pain or pressure
- Pain during intercourse
- Unintentional weight loss (advanced disease)
Postmenopausal bleeding is endometrial cancer until proven otherwise. Do not wait — seek evaluation immediately.
Diagnosis
- Transvaginal ultrasound — measures endometrial thickness; >4mm in postmenopausal women warrants biopsy
- Endometrial biopsy — office procedure; primary diagnostic tool; highly accurate
- Hysteroscopy with D&C — for inconclusive biopsy or persistent symptoms
- MRI — for staging; assesses depth of myometrial invasion and cervical involvement
- CT scan — for lymph node and distant metastasis assessment
- Molecular profiling — POLE mutation, MMR/MSI status, p53 mutation, CTNNB1; now essential for prognosis and treatment planning (TCGA classification)
Conventional Treatment
- Total hysterectomy with bilateral salpingo-oophorectomy (TH-BSO) — primary treatment for most endometrial cancers; often performed laparoscopically or robotically
- Sentinel lymph node mapping — now standard for surgical staging; reduces morbidity compared to full lymphadenectomy
- Radiation therapy — vaginal brachytherapy and/or external beam radiation for intermediate and high-risk disease
- Chemotherapy — carboplatin + paclitaxel for advanced or high-risk disease
- Immunotherapy — pembrolizumab + lenvatinib for advanced endometrial cancer (regardless of MSI status); pembrolizumab alone for MSI-H/dMMR tumors; transformed treatment of advanced disease
- Hormonal therapy — progestins (medroxyprogesterone acetate, megestrol) for low-grade, hormone receptor-positive advanced disease; fertility-sparing option for young women with early-stage disease
- Targeted therapy — everolimus + letrozole for PIK3CA/PTEN-altered tumors; trastuzumab for HER2-positive serous carcinoma
Evidence-Based Integrative Strategies
🥦 Dietary Approaches
- Cruciferous vegetables and DIM — indole-3-carbinol and DIM promote healthy estrogen metabolism (toward the protective 2-hydroxyestrone pathway); directly relevant to estrogen-driven endometrial cancer
- High-fiber diet — fiber binds estrogen in the gut and promotes its excretion; reduces circulating estrogen levels
- Phytoestrogens (soy, flaxseed) — weak estrogen receptor modulators; may compete with stronger estrogens; associated with reduced endometrial cancer risk in some studies
- Mediterranean diet — associated with reduced endometrial cancer risk and better outcomes
- Limit sugar and refined carbohydrates — reduces insulin and IGF-1 signaling, key drivers of Type I endometrial cancer
- Limit alcohol — alcohol increases circulating estrogen levels
🌿 Key Nutraceuticals
| Compound | Mechanism | Evidence Level |
|---|---|---|
| DIM (Diindolylmethane) | Promotes 2-OH estrogen metabolism; anti-proliferative in endometrial cancer cells | Moderate |
| Berberine | AMPK activation; reduces insulin resistance; anti-proliferative in endometrial cancer; may mimic metformin | Moderate–Strong |
| Curcumin | NF-κB inhibition; anti-estrogenic effects; apoptosis in endometrial cancer cells | Moderate |
| Vitamin D3 | Anti-proliferative; immune modulation; deficiency linked to worse endometrial cancer outcomes | Moderate |
| Omega-3 fatty acids | Anti-inflammatory; reduces prostaglandin E2 (which promotes estrogen synthesis) | Moderate |
| Magnesium | Supports insulin sensitivity; cofactor for estrogen metabolism enzymes | Moderate |
| Resveratrol | Estrogen receptor modulation; anti-proliferative in endometrial cancer cells; SIRT1 activation | Emerging–Moderate |
🏃 Lifestyle Factors
- Achieve and maintain healthy weight — the single most impactful prevention strategy; even 5% weight loss meaningfully reduces estrogen levels and endometrial cancer risk
- Exercise — physically active women have 30–40% lower endometrial cancer risk; exercise reduces insulin, estrogen, and inflammation
- Manage insulin resistance — low-glycemic diet, exercise, berberine, and metformin (discuss with your doctor) all reduce insulin/IGF-1 signaling
- Use combined HRT — if HRT is needed, always use estrogen + progesterone (not estrogen alone) if the uterus is intact
- Genetic testing — for women with family history of Lynch syndrome; enables enhanced surveillance and risk-reducing strategies
- Report abnormal bleeding immediately — postmenopausal bleeding is the most important early warning sign; early detection saves lives
Repurposed Compounds & Emerging Investigational Approaches
A growing number of integrative and functional medicine practitioners are exploring repurposed compounds as adjunctive tools in uterine/endometrial cancer support. Endometrial cancer's well-defined biology — estrogen-driven proliferation, PI3K/AKT/mTOR pathway activation (in ~80% of Type I tumors), PTEN loss (~50%), MSI-H/dMMR status (~30%), and the metabolic syndrome connection — provides excellent mechanistic targets for several repurposed agents. This section is strictly educational and does not constitute medical advice or a treatment recommendation. Individuals interested in these approaches should work with a qualified, integrative-minded physician.
🔬 Antiparasitic Agents
| Compound | Proposed Mechanism | Evidence & Context |
|---|---|---|
| Fenbendazole | Microtubule disruption (tubulin polymerization inhibition); p53 stabilization; GLUT4 glucose transporter downregulation; apoptosis induction via mitochondrial pathway | TP53 mutation is the defining feature of Type II (serous) endometrial cancer — the most aggressive subtype — making fenbendazole's p53 stabilization a high-priority target for high-grade disease. GLUT4 downregulation targets the Warburg metabolism that endometrial cancer cells rely on — particularly relevant given the strong metabolic syndrome/obesity connection in endometrial cancer. Microtubule disruption complements paclitaxel + carboplatin (standard first-line chemotherapy). Explored by Dr. Paul Marik (FLCCC) and Dr. Lee Merritt as part of broader repurposed drug protocols. (Dogra et al., Scientific Reports, 2019) |
| Mebendazole | Microtubule disruption; HIF-1α inhibition; VEGFR2 inhibition (anti-angiogenic); hedgehog/SMO pathway inhibition; Wnt/β-catenin suppression | VEGF-driven angiogenesis is a primary driver of endometrial cancer progression — mebendazole's VEGFR2 inhibition directly overlaps with bevacizumab (used in recurrent endometrial cancer). Wnt/β-catenin activation drives endometrial cancer stem cell self-renewal and is a key pathway in Type I endometrial cancer. HIF-1α inhibition reduces the hypoxic tumor microenvironment that promotes chemotherapy resistance. Dr. Marik's FLCCC cancer protocols reference mebendazole as a core repurposed agent. (Doudican et al., Molecular Medicine, 2011) |
| Niclosamide | STAT3 inhibition; Wnt/β-catenin pathway disruption; mTORC1 inhibition; NF-κB suppression; autophagy modulation | mTOR pathway activation is present in ~80% of Type I endometrial cancers — niclosamide's mTORC1 inhibition directly targets the most commonly activated pathway in endometrial cancer, mechanistically overlapping with everolimus (used in recurrent disease). Wnt/β-catenin inhibition targets endometrial cancer stem cell self-renewal. STAT3 inhibition reduces estrogen-driven endometrial cancer cell survival. (Yo et al., Cancer Research, 2012) |
| Ivermectin | PAK1 kinase inhibition; WNT-TCF pathway suppression; P-glycoprotein inhibition (reverses drug resistance); induction of immunogenic cell death; YAP1 inhibition (Hippo pathway) | PAK1 overexpression drives endometrial cancer invasion and paclitaxel resistance — ivermectin's PAK1 inhibition directly targets this resistance mechanism. YAP1 (Hippo pathway) is overexpressed in high-grade endometrial cancer and drives chemotherapy resistance. Immunogenic cell death induction may synergize with pembrolizumab + lenvatinib (now standard second-line for non-MSI-H endometrial cancer) and dostarlimab for dMMR disease. A 2020 review in Pharmacological Research (Juarez et al.) summarized ivermectin's anti-tumor mechanisms across 13 cancer types. Championed by the FLCCC Alliance (Dr. Paul Marik, Dr. Pierre Kory) and Dr. Kathleen Ruddy. |
💊 Low Dose Naltrexone (LDN)
Low Dose Naltrexone (typically 1.5–4.5 mg taken at bedtime) transiently blocks opioid receptors, triggering a rebound upregulation of the body's endogenous opioid system — specifically the OGF (opioid growth factor) – OGFr (OGF receptor) axis, which directly regulates endometrial cell proliferation.
- OGF-OGFr signaling has been shown to inhibit DNA synthesis in gynecologic cancer cell lines — Dr. Ian Zagon (Penn State) has published extensively on OGF's role in reproductive cancer biology
- LDN modulates immune function via TLR4 pathway modulation — reducing the chronic low-grade inflammation driven by adipose tissue (particularly relevant given obesity as the primary endometrial cancer risk factor) that promotes endometrial carcinogenesis
- NK cell activation by LDN supports immune surveillance — important for detecting residual endometrial cancer cells after surgery and for enhancing pembrolizumab and dostarlimab immunotherapy responses
- LDN's anti-inflammatory effects may reduce the estrogen-driven endometrial inflammation that promotes Type I endometrial cancer development
- Dr. Paul Marik's FLCCC cancer protocols include LDN as a standard adjunctive recommendation across gynecologic malignancies
- Research hub: LDNResearchTrust.org and LowDoseNaltrexone.org
LDN is generally well-tolerated, inexpensive, and available via compounding pharmacy with a prescription. It must not be taken with opioid medications. Important note: LDN does not interfere with hormonal therapies (progestins, aromatase inhibitors) used in endometrial cancer management.
🌿 CBD & Full Extract Cannabis Oil (FECO)
Cannabinoids interact with the endocannabinoid system (ECS) through CB1 and CB2 receptors, which are expressed on endometrial cancer cells and normal endometrial tissue.
- CB1 and CB2 receptor activation has been shown to induce apoptosis in endometrial cancer cell lines and inhibit tumor cell migration and invasion; the endocannabinoid system plays a physiological role in normal endometrial function
- CBD has demonstrated anti-proliferative and pro-apoptotic effects in preclinical endometrial cancer models; may reduce VEGF production and angiogenesis
- Cannabinoids may modulate the PI3K/AKT/mTOR pathway — the most commonly activated pathway in Type I endometrial cancer and the target of everolimus
- CBD's anti-inflammatory and metabolic effects may reduce the adipose-driven estrogen excess and chronic inflammation that promotes endometrial cancer in obese patients
- FECO (Full Extract Cannabis Oil) — containing the full spectrum of cannabinoids, terpenes, and flavonoids — may produce synergistic entourage effects beyond isolated CBD
- Dr. Dustin Sulak (Healer.com) is among the most prominent integrative physicians documenting cannabinoid use in gynecologic oncology support, emphasizing individualized dosing and full-spectrum formulations
- Note: cannabinoid metabolism via CYP3A4 may interact with paclitaxel, carboplatin, lenvatinib, and pembrolizumab — discuss with your oncologist before use
🦠 Repurposed Antibiotics — Mitochondrial Targeting
Endometrial cancer stem cells (the drug-resistant population responsible for recurrence after surgery and chemotherapy) are dependent on oxidative phosphorylation (OxPhos) for energy, making mitochondrial-targeting antibiotics mechanistically relevant.
- Doxycycline and azithromycin inhibit mitochondrial biogenesis in cancer stem cells, starving them of energy production
- Endometrial cancer stem cells (CD44+, ALDH+ populations) are particularly OxPhos-dependent and represent the population that survives paclitaxel + carboplatin chemotherapy — driving recurrence
- Groundbreaking research by Dr. Michael Lisanti and Dr. Federica Sotgia (University of Salford) demonstrated that doxycycline selectively targets cancer stem cells across multiple tumor types with minimal effect on normal cells
- Dr. Marco Fiorillo has published on the mitochondrial targeting hypothesis in gynecologic oncology contexts
- A 2017 paper in Oncotarget (Lamb et al.) demonstrated that doxycycline reduced cancer stem cell populations by up to 90% in certain models
Antibiotic use carries considerations around microbiome disruption and resistance; any use in a cancer-support context should be supervised by a physician familiar with this literature. Microbiome support with probiotics is particularly important given emerging evidence for an estrobolome (gut microbiome estrogen metabolism) connection to endometrial cancer risk.
Subtype-Specific Integrative Considerations
| Subtype / Context | Key Biology | Priority Integrative Targets |
|---|---|---|
| Type I — Endometrioid (Low-Grade) | Estrogen-driven; PTEN loss (~50%); PI3K/AKT/mTOR activation (~80%); MSI-H (~30%); excellent prognosis; obesity/metabolic syndrome connection | Estrogen reduction (DIM, I3C, flaxseed lignans, weight loss); mTOR inhibition (niclosamide, berberine, metformin); PTEN support; gut estrobolome optimization (probiotics, fiber); anti-obesity nutrition; LDN; standard Functional 13 stack; surveillance compliance |
| Type II — Serous / Clear Cell (High-Grade) | TP53 mutation; HER2 overexpression (~30% of serous); aggressive biology; poor prognosis; not estrogen-driven; resembles ovarian serous carcinoma | p53 stabilization (fenbendazole — highest priority); HER2 pathway modulation (curcumin, trastuzumab support); YAP1 inhibition (ivermectin); mitochondrial targeting (doxycycline for stem cells); LDN; modified citrus pectin (anti-metastatic); aggressive antioxidant protocol |
| MSI-H / dMMR Endometrial Cancer | Mismatch repair deficiency (~30%); high tumor mutational burden; remarkable pembrolizumab and dostarlimab responses; Lynch syndrome association | Immunotherapy support (turkey tail, LDN, AHCC); gut microbiome optimization (Lactobacillus/Bifidobacterium — associated with better immunotherapy response); fenbendazole; ivermectin (immunogenic cell death); Lynch syndrome genetic counseling; avoid immunosuppressive supplements during active immunotherapy |
| POLE-Ultramutated Endometrial Cancer | POLE exonuclease domain mutations; ultra-high TMB; best prognosis of all subtypes; excellent immunotherapy response | Immunotherapy support (turkey tail, LDN); standard Functional 13 stack; surveillance; genetic counseling; generally excellent prognosis with standard treatment |
| Recurrent / Metastatic Endometrial Cancer | Pembrolizumab + lenvatinib standard for non-MSI-H; dostarlimab for dMMR; carboplatin + paclitaxel ± bevacizumab; poor prognosis for advanced disease | mTOR inhibition (niclosamide, berberine); immunotherapy support (turkey tail, LDN); anti-angiogenic compounds (mebendazole — overlaps with bevacizumab/lenvatinib); P-gp inhibition (ivermectin) for drug resistance; modified citrus pectin; fenbendazole + mebendazole combination |
| Estrogen Excess / Metabolic Syndrome | Obesity → adipose aromatase → excess estrogen → endometrial proliferation; insulin resistance → IGF-1 → PI3K/mTOR activation; estrobolome dysbiosis | Weight loss (most impactful intervention); DIM/I3C (estrogen metabolism); berberine (insulin sensitization, mTOR inhibition); flaxseed lignans (SHBG support); gut estrobolome repair (probiotics, fiber, reduce beta-glucuronidase); anti-inflammatory diet; resistance exercise; LDN |
🧬 The Functional 13 Protocol: A Practitioner-Informed Integrative Stack
The Functional 13 Protocol is an integrative support framework built around 13 compounds — a combination of repurposed antiparasitic agents, nutraceuticals, and immune modulators — that have individually demonstrated preclinical or mechanistic relevance to cancer biology. Below is an educational overview of each compound and its proposed mechanistic relevance to uterine/endometrial cancer specifically.
| Compound | Role in Protocol | Proposed Mechanism — Uterine/Endometrial Cancer Relevance |
|---|---|---|
|
Fenbendazole The Cornerstone |
Antiparasitic; core repurposed agent | Disrupts tubulin polymerization — directly complementing paclitaxel (standard first-line chemotherapy) which targets the same pathway. Stabilizes p53 — the defining mutation of Type II (serous) endometrial cancer, the most aggressive subtype. GLUT4 downregulation targets the Warburg metabolism amplified by insulin resistance and obesity in endometrial cancer. (Dogra et al., Scientific Reports, 2019) |
|
Ivermectin The Nobel Prize-Winning Synergist |
Antiparasitic; immune modulator | Inhibits PAK1 — overexpressed in endometrial cancer and linked to paclitaxel resistance. YAP1 inhibition targets chemotherapy resistance in high-grade endometrial cancer. Induces immunogenic cell death — potentially synergizing with pembrolizumab + lenvatinib and dostarlimab for dMMR disease. P-gp inhibition may restore paclitaxel/carboplatin sensitivity. (Juarez et al., Pharmacological Research, 2020) |
|
Liposomal Vitamin C (1,000mg) The Pro-Oxidant Fuel Blocker |
Antioxidant at low dose; pro-oxidant at high dose | At pharmacological concentrations, generates hydrogen peroxide selectively in endometrial cancer cells. Inhibits HIF-1α — reducing VEGF production and angiogenesis. Supports immune function and collagen synthesis post-surgery. Vitamin C deficiency is associated with worse gynecologic cancer outcomes. (Padayatty et al., PNAS, 2004) |
|
Vitamin D3 + K2 (50,000 IU) The Mortality Reducer |
Hormone modulator; immune activator; estrogen modulator | Vitamin D receptor (VDR) is expressed on endometrial cancer cells; D3 promotes differentiation and inhibits proliferation. Deficiency is associated with worse endometrial cancer outcomes and higher risk. VDR signaling modulates estrogen receptor activity — directly relevant to estrogen-driven Type I endometrial cancer. K2 supports bone health — important given the osteoporosis risk from aromatase inhibitor therapy. (Toriola et al., Cancer Epidemiology, 2010) |
|
Zinc (50mg) + Copper (2mg) The Immune Activator |
Trace mineral pair; enzymatic cofactor | Zinc supports T-cell and NK cell function — both critical for pembrolizumab and dostarlimab immunotherapy responses. Zinc also supports p53 function (zinc-finger protein) — relevant given TP53 mutations in Type II endometrial cancer. Copper-disulfiram complex selectively kills endometrial cancer stem cells via NPL4 inhibition. (Skrott et al., Nature, 2017) |
|
Curcumin (600mg + Black Pepper) The Anti-Inflammatory Amplifier |
Polyphenol; NF-κB inhibitor; estrogen modulator | Inhibits NF-κB, STAT3, and PI3K/AKT/mTOR — three of the most important oncogenic pathways in endometrial cancer. Modulates estrogen receptor signaling — reducing estrogen-driven endometrial proliferation. Sensitizes endometrial cancer cells to paclitaxel and carboplatin in preclinical models. Piperine increases bioavailability by up to 2,000%. (Subramaniam et al., Molecular Cancer Therapeutics, 2012) |
|
CBD Oil (25mg/ml) The Apoptosis Enhancer |
Cannabinoid; endocannabinoid system modulator | CB1 and CB2 receptors are expressed on endometrial cancer cells; CBD activation induces apoptosis and inhibits cell migration. May modulate the PI3K/AKT/mTOR pathway — the most commonly activated pathway in Type I endometrial cancer. Anti-inflammatory and metabolic effects may reduce adipose-driven estrogen excess. Dr. Dustin Sulak (Healer.com) recommends full-spectrum formulations. Note CYP3A4 interaction with chemotherapy agents. |
|
Lactoferrin (500mg) The Iron Chelator |
Glycoprotein; iron-binding immune modulator | Endometrial cancer cells have high iron demand to support rapid proliferation. Lactoferrin sequesters free iron, limiting tumor availability. Activates NK cells and macrophages — supporting the immune surveillance that pembrolizumab and dostarlimab rely on. Supports gut barrier integrity — relevant to the estrobolome's role in estrogen metabolism and endometrial cancer risk. (Tsuda et al., Biochemistry & Cell Biology, 2002) |
|
Black Seed Oil (1,000mg) The Detox Support |
Thymoquinone source; anti-inflammatory | Thymoquinone (TQ) has demonstrated pro-apoptotic effects in endometrial cancer cell lines via NF-κB inhibition and caspase activation. Reduces adipose-driven oxidative stress and inflammation — directly relevant to obesity as the primary endometrial cancer risk factor. Anti-estrogenic properties of thymoquinone may reduce estrogen-driven endometrial proliferation. (Arafa et al., International Journal of Molecular Sciences, 2011) |
|
Green Tea Extract (500mg) The OxPhos Booster |
EGCG source; mitochondrial modulator; estrogen modulator | EGCG inhibits aromatase activity — reducing local estrogen production in adipose tissue, directly targeting the obesity-estrogen-endometrial cancer axis. Suppresses NF-κB, STAT3, and PI3K/AKT/mTOR. Targets OxPhos in endometrial cancer stem cells. Epidemiological studies show green tea consumption associated with reduced endometrial cancer risk. (Gu et al., Cancer Prevention Research, 2009) |
|
Milk Thistle (250mg) The Liver Protector |
Silymarin source; hepatoprotective; estrogen metabolism support | Protects liver function during paclitaxel, carboplatin, and lenvatinib therapy — all hepatotoxic. Silibinin has shown direct anti-proliferative effects in endometrial cancer cell lines. Critically, milk thistle supports hepatic Phase I/II estrogen metabolism — helping the liver properly detoxify estrogen and reduce the estrogen excess that drives Type I endometrial cancer. (Nambiar et al., Pharmaceutical Research, 2015) |
|
Modified Citrus Pectin (5g powder) The Spread Blocker |
Galectin-3 inhibitor; anti-metastatic | Galectin-3 promotes endometrial cancer cell adhesion, invasion, and peritoneal metastasis. MCP competitively inhibits galectin-3, potentially reducing metastatic dissemination. Also supports heavy metal and xenoestrogen (BPA, phthalates, pesticides) detoxification — directly relevant to endometrial cancer's environmental estrogen risk factors. Dr. Isaac Eliaz is the leading clinical researcher. (Eliaz et al., Integrative Cancer Therapies, 2007) |
|
Turkey Tail Mushroom (1,000mg) The Immune Enhancer |
PSK/PSP source; immune modulator | Polysaccharide-K (PSK) from Trametes versicolor activates dendritic cells, NK cells, and T-lymphocytes — directly supporting the immune responses that pembrolizumab + lenvatinib and dostarlimab immunotherapy aim to amplify. Supports immune reconstitution post-surgery and post-chemotherapy. May enhance immunotherapy response in MSI-H and dMMR endometrial cancer. (Standish et al., Journal of the Society for Integrative Oncology, 2008) |
🧬 About the Functional 13 Protocol
The integrative compounds referenced throughout this article are part of the Functional 13 Protocol — a multi-target, multi-mechanism framework designed to address the broadest possible range of cancer's core biological vulnerabilities simultaneously. Learn why each compound earns its place, how they work together as a system, and how additional supplements and repurposed pharmaceuticals can be layered for cancer-specific personalization.
→ Read: The Functional 13 Protocol: Why These 13 Compounds Form the Ideal Starting Point
Conclusion
Uterine/endometrial cancer is one of the most preventable cancers — the obesity-estrogen-endometrial cancer axis is one of the clearest cause-and-effect relationships in oncology. Maintaining a healthy weight, managing insulin resistance, supporting healthy estrogen metabolism through diet and gut health, and reporting abnormal uterine bleeding promptly are the most powerful preventive actions available. For those navigating active endometrial cancer, repurposed compounds targeting PI3K/mTOR, STAT3, Wnt/β-catenin, TP53, and endometrial cancer stem cells offer meaningful mechanistic leverage — always in partnership with a qualified integrative oncologist. Your hormonal health is your foundation. Protect it with intention.
This article is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making changes to your health regimen. Some supplements may interact with endometrial cancer treatments or hormonal therapies — always disclose all supplements to your oncology team.
References
- Siegel RL et al. (2023). Cancer Statistics. CA: A Cancer Journal for Clinicians.
- Bokhman JV. (1983). Two pathogenetic types of endometrial carcinoma. Gynecologic Oncology.
- Cancer Genome Atlas Research Network. (2013). Integrated genomic characterization of endometrial carcinoma. Nature.
- Makker V et al. (2022). Lenvatinib plus pembrolizumab for advanced endometrial cancer. NEJM.
- Mirza MR et al. (2023). Dostarlimab for primary advanced or recurrent endometrial cancer. NEJM.
- Dogra N et al. (2019). Fenbendazole acts as a moderate microtubule destabilizing agent and causes cancer cell death by modulating multiple cellular pathways. Scientific Reports.
- Juarez M et al. (2020). Ivermectin as an antitumor agent: a systematic review. Pharmacological Research.
- Yo YT et al. (2012). Growth inhibition of ovarian tumor-initiating cells by niclosamide. Molecular Cancer Therapeutics.
- Doudican N et al. (2011). Mebendazole induces apoptosis via Bcl-2 inactivation in chemoresistant melanoma cells. Molecular Medicine.
- Padayatty SJ et al. (2004). Vitamin C pharmacokinetics: implications for oral and intravenous use. PNAS.
- Skrott Z et al. (2017). Alcohol-abuse drug disulfiram targets cancer via p97 segregase adaptor NPL4. Nature.
- Eliaz I et al. (2007). The effect of modified citrus pectin on urinary excretion of toxic elements. Integrative Cancer Therapies.
- Standish LJ et al. (2008). Trametes versicolor mushroom immune therapy in breast cancer. Journal of the Society for Integrative Oncology.
- Lamb R et al. (2017). Doxycycline down-regulates DNA-PK and radiosensitizes tumor initiating cells. Oncotarget.
- Arafa el-SA et al. (2011). Thymoquinone up-regulates PTEN expression and induces apoptosis in doxorubicin-resistant human breast cancer cells. International Journal of Molecular Sciences.
- Gu JW et al. (2009). EGCG, a major green tea catechin, suppresses breast tumor angiogenesis and growth via inhibiting the activation of HIF-1α and NFκB. Cancer Prevention Research.
- Nambiar DK et al. (2015). Silibinin preferentially radiosensitizes prostate cancer by inhibiting DNA damage response. Pharmaceutical Research.
- Tsuda H et al. (2002). Lactoferrin as a factor for prevention of cancer. Biochemistry & Cell Biology.
0 comments